Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis |
| |
| Authors: | Jeyakumar M Butters T D Dwek R A Platt F M |
| |
| Affiliation: | Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, UK. |
| |
| Abstract: | Paediatric neurodegenerative diseases are frequently caused by inborn errors in glycosphingolipid (GSL) catabolism and are collectively termed the glycosphingolipidoses. GSL catabolism occurs in the lysosome and a defect in an enzyme involved in GSL degradation leads to the lysosomal storage of its substrate(s). GSLs are abundantly expressed in the central nervous system (CNS) and the disorders frequently have a progressive neurodegenerative course. Our understanding of pathogenesis in these diseases is incomplete and currently few options exist for therapy. In this review we discuss how mouse models of these disorders are providing insights into pathogenesis and also leading to progress in evaluating experimental therapies. |
| |
| Keywords: | Lysosomal storage disease pathogenesis glycosphingolipid biosynthesis inhibitors substrate reduction therapy gangliosides |
| 本文献已被 PubMed 等数据库收录！ |
